4.7 Article

Engineering Multiple U7snRNA Constructs to Induce Single and Multiexon-skipping for Duchenne Muscular Dystrophy

Journal

MOLECULAR THERAPY
Volume 20, Issue 6, Pages 1212-1221

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/mt.2012.26

Keywords

-

Funding

  1. UK Medical Research Council
  2. Muscular Dystrophy Campaign
  3. Muscular Dystrophy Association USA
  4. Association Monegasque contre les myopathies
  5. Duchenne Parent project France
  6. Medical Research Council [MC_U137761449, G0801763] Funding Source: researchfish
  7. MRC [G0801763, MC_U137761449] Funding Source: UKRI

Ask authors/readers for more resources

Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD but still faces personalized medicine challenges as different mutations found in DMD patients require skipping of different exons. However, 70% of DMD patients harbor dystrophin gene deletions in a mutation-rich area or hot-spot in the central genomic region. In this study, we have developed 11 different U7 small-nuclear RNA, to shuttle antisense sequences designed to mask key elements involved in the splicing of exons 45 to 55. We demonstrate that these constructs induce efficient exon skipping both in vitro in DMD patients' myoblasts and in vivo in human DMD (hDMD) mice and that they can be combined into a single vector to achieve a multi skipping of at least 3 exons. These very encouraging results provide proof of principle that efficient multiexon-skipping can be achieved using adeno-associated viral (AAV) vectors encoding multiple U7 small-nuclear RNAs (U7snRNAs), offering therefore very promising tools for clinical treatment of DMD.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Editorial Material Multidisciplinary Sciences

RNA-targeted drugs for neuromuscular diseases

Alessandra Ferlini, Aurelie Goyenvalle, Francesco Muntoni

SCIENCE (2021)

Correction Genetics & Heredity

Pathological mechanism and antisense oligonucleotide-mediated rescue of a non-coding variant suppressing factor 9 RNA biogenesis leading to hemophilia B (vol 16, e1008690, 2020)

Simon Krooss, Sonja Werwitzke, Johannes Kopp, Alice Rovai, Dirk Varnholt, Amelie S. Wachs, Aurelie Goyenvalle, Annemieke Aartsma-Rus, Michael Ott, Andreas Tiede, Jorg Langemeier, Jens Bohne

PLOS GENETICS (2021)

Review Medicine, Research & Experimental

Delivery of oligonucleotide-based therapeutics: challenges and opportunities

Suzan M. Hammond, Annemieke Aartsma-Rus, Sandra Alves, Sven E. Borgos, Ronald A. M. Buijsen, Rob W. J. Collin, Giuseppina Covello, Michela A. Denti, Lourdes R. Desviat, Lucia Echevarria, Camilla Foged, Gisela Gaina, Alejandro Garanto, Aurelie T. Goyenvalle, Magdalena Guzowska, Irina Holodnuka, David R. Jones, Sabine Krause, Taavi Lehto, Marisol Montolio, Willeke Van Roon-Mom, Virginia Arechavala-Gomeza

Summary: The field of nucleic acid-based therapeutics has seen rapid development in recent years, with the main challenge being delivery to target tissues. The adoption of delivery technologies, such as conjugates or nanoparticles, has been a game changer for many therapeutic indications.

EMBO MOLECULAR MEDICINE (2021)

Article Neurosciences

Altered visual processing in the mdx52 mouse model of Duchenne muscular dystrophy

Mirella Telles Salgueiro Barboni, Andre Mauricio Passos Liber, Anneka Joachimsthaler, Amel Saoudi, Aurelie Goyenvalle, Alvaro Rendon, Jerome E. Roger, Dora Fix Ventura, Jan Kremers, Cyrille Vaillend

Summary: The mdx52 mouse model of Duchenne muscular dystrophy lacks exon 52 of the DMD gene, which leads to the loss of certain dystrophin proteins and visual abnormalities. In this study, mdx52 mice showed reduced amplitudes and delayed implicit times in their ERG responses, as well as diminished responses to various stimuli in both dark-adapted and light-adapted conditions. Their contrast sensitivity was also significantly reduced at 50% contrast. These findings suggest that the mdx52 mouse model may be useful for studying retinal dystrophins and related preclinical studies on DMD.

NEUROBIOLOGY OF DISEASE (2021)

Review Medicine, Research & Experimental

RNA splicing modulation: Therapeutic progress and perspectives

Amel Saoudi, Aurelie Goyenvalle

Summary: Advances in genetic and genomic research have led to a better understanding of hereditary diseases attributed to aberrant splicing, making them ideal targets for RNA modulation therapies. Novel strategies like exon skipping or re-inclusion during splicing have shown promise in the clinic, particularly in treating neuromuscular diseases. Further research into improving the biodistribution of antisense oligonucleotides and exploring alternative chemistries or delivery systems is ongoing to overcome current limitations in splicing therapies.

M S-MEDECINE SCIENCES (2021)

Article Biochemistry & Molecular Biology

Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides

Karima Relizani, Lucia Echevarria, Faouzi Zarrouki, Cecile Gastaldi, Chloe Dambrune, Philippine Aupy, Adrian Haeberli, Marek Komisarski, Thomas Tensorer, Thibaut Larcher, Fedor Svinartchouk, Cyrille Vaillend, Luis Garcia, Aurelie Goyenvalle

Summary: Tricyclo-DNA (tcDNA) is a promising oligonucleotide analog with therapeutic potential, especially when conjugated with palmitic acid for improved delivery to muscle tissues. This conjugation enhances the potency of tcDNA-ASO, resulting in functional improvement in dystrophic mice with significantly reduced dose, while also showing a promising safety profile for clinical development in neuromuscular diseases.

NUCLEIC ACIDS RESEARCH (2022)

Article Clinical Neurology

Partial Restoration of Brain Dystrophin and Behavioral Deficits by Exon Skipping in the Muscular Dystrophy X-Linked (mdx) Mouse

Faouzi Zarrouki, Karima Relizani, Flavien Bizot, Thomas Tensorer, Luis Garcia, Cyrille Vaillend, Aurelie Goyenvalle

Summary: This study aimed to evaluate whether restoring brain dystrophin could alleviate cognitive and behavioral deficits associated with Duchenne muscular dystrophy. The results showed that exon skipping treatment in mdx mice significantly reduced fear responses and improved long-term memory retention.

ANNALS OF NEUROLOGY (2022)

Review Cardiac & Cardiovascular Systems

Common and Rare 5′UTR Variants Altering Upstream Open Reading Frames in Cardiovascular Genomics

Omar Soukarieh, Caroline Meguerditchian, Carole Proust, Dylan Aissi, Melanie Eyries, Aurelie Goyenvalle, David-Alexandre Tregouet

Summary: HTS technologies are transforming research and molecular diagnostics by exploring millions of nucleotide sequences, focusing on identifying genetic variations contributing to rare and common human diseases. The study highlights the importance of 5'UTR variants altering upORFs and their association with rare cardiovascular disorders.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Article Biochemistry & Molecular Biology

Abnormal Expression of Synaptic and Extrasynaptic GABAA Receptor Subunits in the Dystrophin-Deficient mdx Mouse

Faouzi Zarrouki, Sebastien Goutal, Ophelie Vacca, Luis Garcia, Nicolas Tournier, Aurelie Goyenvalle, Cyrille Vaillend

Summary: This study found that the loss of dystrophin in a mouse model of Duchenne muscular dystrophy (DMD) affects not only the stability of synaptic GABA(A) receptors, but also the composition and expression of subunits at both synaptic and extrasynaptic sites. These findings provide new measures to evaluate compensation for nervous system alterations in DMD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Multidisciplinary Sciences

Dystrophin myonuclear domain restoration governs treatment efficacy in dystrophic muscle

Adrien Morin, Amalia Stantzou, Olga N. Petrova, John Hildyard, Thomas Tensorer, Meriem Matouk, Mina V. Petkova, Isabelle Richard, Tudor Manoliu, Aurelie Goyenvalle, Sestina Falcone, Markus Schuelke, Corinne Laplace-Builhe, Richard J. Piercy, Luis Garcia, Helge Amthor

Summary: Dystrophin is crucial for muscle health, but its spatial organization is not well understood. Studying fluorescently tagged dystrophin in mice, researchers discovered that dystrophin is compartmentalized in sarcolemmal territories. At myotendinous junctions, Dmd transcripts and dystrophin protein are enriched. Genomic correction restored separated dystrophin domains, while transcript-level correction restored dystrophin initially at junctions before extending along the entire fiber. This research suggests that widespread restoration of fiber dystrophin, especially at muscle-tendon junctions, is critical for therapeutic success in DMD.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Article Biochemistry & Molecular Biology

Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides

Aurelie Goyenvalle, Cecilia Jimenez-Mallebrera, Willeke van Roon, Sabine Sewing, Arthur M. Krieg, Virginia Arechavala-Gomeza, Patrik Andersson

Summary: The field of nucleic acid therapeutics has seen significant progress, but early assessments of toxicity have often been neglected. Consensus recommendations have been proposed to evaluate the toxicity of nucleic acid drugs in early stages, including the use of predictive in vitro and ex vivo assays to filter out potentially toxic candidates before animal studies.

NUCLEIC ACID THERAPEUTICS (2023)

Article Medicine, Research & Experimental

Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx mice

Flavien Bizot, Remko Goossens, Thomas Tensorer, Sergei Dmitriev, Luis Garcia, Annemieke Aartsma-Rus, Pietro Spitali, Aurelie Goyenvalle

Summary: This study found that histone deacetylase inhibitors can correct the imbalance of transcripts in patients with Duchenne muscular dystrophy, and the combined therapy with antisense oligonucleotides can significantly improve the restoration levels of dystrophin.

MOLECULAR THERAPY-NUCLEIC ACIDS (2022)

Article Cell Biology

Oligonucleotide Enhancing Compound Increases Tricyclo-DNA Mediated Exon-Skipping Efficacy in the Mdx Mouse Model

Flavien Bizot, Abdallah Fayssoil, Cecile Gastaldi, Tabitha Irawan, Xaysongkhame Phongsavanh, Arnaud Mansart, Thomas Tensorer, Elise Brisebard, Luis Garcia, Rudolph L. Juliano, Aurelie Goyenvalle

Summary: Nucleic acid-based therapeutics show promise for treating diseases like DMD, but face challenges like poor drug distribution and entrapment in the endosomal compartment. Oligonucleotide-enhancing compounds (OEC) can help release drugs and improve nuclear concentration, enhancing the therapeutic potential of exon-skipping approaches. This study demonstrates the potential of a combination therapy involving ASO and OEC for the treatment of DMD.

CELLS (2023)

Article Biochemistry & Molecular Biology

Impact of the Inhibition of Organic Anion Transporter on Tricyclo-DNA-Mediated Exon Skipping in the mdx Mouse Model

Flavien Bizot, Thomas Tensorer, Luis Garcia, Aurelie Goyenvalle

Summary: Preventing renal clearance of ASO using an OAT inhibitor does not improve the therapeutic potential of ASO-mediated exon-skipping approaches for the treatment of DMD.

NUCLEIC ACID THERAPEUTICS (2023)

Article Cell Biology

Emotional behavior and brain anatomy of the mdx52 mouse model of Duchenne muscular dystrophy

Amel Saoudi, Faouzi Zarrouki, Catherine Sebrie, Charlotte Izabelle, Aure'lie Goyenvalle, Cyrille Vaillend

Summary: The exon-52-deleted mdx52 mouse model is critical for studying DMD, showing no gross brain abnormalities but significant behavioral phenotypes like enhanced anxiety and impaired Pavlovian association, similar to problems reported in some DMD patients. These findings suggest the potential of using mdx52 mice for preclinical evaluation of treatments targeting brain dysfunctions in DMD.

DISEASE MODELS & MECHANISMS (2021)

No Data Available